Featured Publications
Food insecurity and bulimia nervosa in the United States
Lydecker JA, Grilo CM. Food insecurity and bulimia nervosa in the United States. International Journal Of Eating Disorders 2019, 52: 735-739. PMID: 30920683, PMCID: PMC6555671, DOI: 10.1002/eat.23074.Peer-Reviewed Original Research
2024
Multiple marginalization, discrimination, and disordered eating among youth aged 10–11
Boswell R, Launius K, Lydecker J. Multiple marginalization, discrimination, and disordered eating among youth aged 10–11. International Journal Of Eating Disorders 2024, 57: 1783-1790. PMID: 38572625, PMCID: PMC11343651, DOI: 10.1002/eat.24211.Peer-Reviewed Original ResearchExperiences of discriminationSexual orientation discriminationSample of youth agesWeight-based discriminationMultiple marginsGender discriminationVulnerable youthAdolescent Brain Cognitive DevelopmentCross-sectional dataParental incomeYouth agesPoor healthElevated weightIncreased disordered eatingYouthIntervention effortsTreating eating disordersDisordered eatingAssociated with disordered eatingDiscrimination experiencesOrientation discriminationRace/ethnicityIncreased oddsDiscriminationLogistic regression
2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2018
Household food insecurity is associated with binge‐eating disorder and obesity
Rasmusson G, Lydecker JA, Coffino JA, White MA, Grilo CM. Household food insecurity is associated with binge‐eating disorder and obesity. International Journal Of Eating Disorders 2018, 52: 28-35. PMID: 30565270, PMCID: PMC6584603, DOI: 10.1002/eat.22990.Peer-Reviewed Original ResearchBinge-eating disorderLow food securityHealthy weightPhysical health problemsHierarchical logistic regressionExcess weightFood insecurityStudy groupHousehold food insecurityObesityPsychiatric treatmentHealth problemsOverall associationBinge eatingPreventative interventionsLogistic regressionReference groupLow-income AmericansOvereatingDisordersAssociationSurvey respondentsGroupBinge